Aegis Capital Comments on Valeant Pharma (VRX) Following Q1 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Valeant Pharmaceuticals International, Inc. (VRX) Tops Q1 EPS by 4c
May 8, 2014 6:03 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q1 EPS of $1.76, $0.04 better than the analyst estimate of $1.72. Revenue for the quarter came in at $1.85 billion, versus $1.04 billion reported last year.
"Our first quarter results demonstrate the strong, durable nature of our diversified business model," stated J. Michael Pearson, chairman and chief executive... More
